Epoprostenol treatment for idiopathic pulmonary arterial hypertension in pregnancy

被引：10

作者：

Garabedian, M. J. ^{[1
]}

Hansen, W. F. ^{[1
]}

Gianferrari, E. A. ^{[1
]}

Lain, K. Y. ^{[1
]}

Fragneto, R. Y. ^{[2
]}

Campbell, C. L. ^{[3
]}

Booth, D. C. ^{[3
]}

机构：

[1] Univ Kentucky, Dept Obstet & Gynecol, Lexington, KY 40536 USA

[2] Univ Kentucky, Dept Anesthesiol, Lexington, KY 40536 USA

[3] Univ Kentucky, Dept Cardiol, Lexington, KY 40536 USA

来源：

JOURNAL OF PERINATOLOGY | 2010年 / 30卷 / 09期

关键词：

idiopathic pulmonary arterial hypertension; epoprostenol; pregnancy; MANAGEMENT; THERAPY;

D O I：

10.1038/jp.2010.15

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Idiopathic pulmonary arterial hypertension is a rare condition associated with significant maternal mortality. We report the management of a 37-year-old multigravida with severe disease using epoprostenol, a multidisciplinary approach, and a planned delivery. Although the patient survived the pregnancy, her pulmonary function significantly worsened. Epoprostenol, a pulmonary vasodilator, should be considered when indicated during pregnancy. Neither fetal nor neonatal harm was identified. Journal of Perinatology (2010) 30, 628-631; doi:10.1038/jp.2010.15

引用

页码：628 / 631

页数：4

共 50 条

[41] Scleroderma pulmonary arterial hypertension: the same as idiopathic pulmonary arterial hypertension?
Khan, Sarah L.
Mathai, Stephen C.
CURRENT OPINION IN PULMONARY MEDICINE, 2023, 29 (05) : 380 - 390
[42] Marked Hemodynamic Improvements by High-Dose Epoprostenol Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension
Akagi, Satoshi
Nakamura, Kazufumi
Miyaji, Katsumasa
Ogawa, Aiko
Kusano, Kengo Fukushima
Ito, Hiroshi
Matsubara, Hiromi
CIRCULATION JOURNAL, 2010, 74 (10) : 2200 - 2205
[43] Successful pregnancy and delivery in a patient with vasoreactive idiopathic pulmonary arterial hypertension
Sillesen, Anne-Sophie
Vejlstrup, Niels
Kornhall, Bjorn
Andersen, Lars Willy
Sharif, Heidi
Carlsen, Jorn
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (01) : E84 - E85
[44] Treatment with epoprostenol of pulmonary arterial hypertension following mitral valve replacement for mitral stenosis
Elliott, CG
Palevsky, HI
THORAX, 2004, 59 (06) : 536 - 537
[45] Epoprostenol treatment in children with severe pulmonary hypertension
Lammers, Astrid E.
Hislop, Alison A.
Flynn, Yvette
Haworth, Sheila G.
HEART, 2007, 93 (06) : 739 - 743
[46] Pulmonary arterial hypertension: Patient transition from epoprostenol to bosentan
Bshouty, Z
Da Ponte, FM
CHEST, 2003, 124 (04) : 89S - 89S
[47] Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
Sitbon, Olivier
Noordegraaf, Anton Vonk
EUROPEAN RESPIRATORY REVIEW, 2017, 26 (143):
[48] Epoprostenol Use for Pulmonary Arterial Hypertension in the Palliative Care Setting
Wozencraft, Colin P.
Coyne, Patrick J.
Grinnan, Daniel C.
Morel, Thomas D.
Muzevich, Katie M.
Smith, Thomas J.
JOURNAL OF PALLIATIVE MEDICINE, 2012, 15 (05) : 619 - 622
[49] Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension
Chin, Kelly M.
Channick, Richard N.
de Lemos, James A.
Kim, Nick H.
Torres, Fernando
Rubin, Lewis J.
CHEST, 2009, 135 (01) : 130 - 136
[50] Epoprostenol/tozinameranAcute exacerbation of pulmonary arterial hypertension and no therapeutic response
Reactions Weekly, 2024, 1993 (1) : 72 - 72

← 1 2 3 4 5 →